Ar­genx buoyed by PhII tri­al re­sults; Boehringer touts a big batch of re­al-world COPD da­ta

→ Shares of Bel­gium’s ar­genx $ARGX edged up this morn­ing as the com­pa­ny tout­ed top-line da­ta from its Phase II study of ef­gar­tigi­mod (ARGX-113) in adult pri­ma­ry im­mune throm­bo­cy­tope­nia pa­tients. Re­searchers said that the drug spurred “clin­i­cal­ly mean­ing­ful platelet count im­prove­ments across dos­es and ITP pa­tient clas­si­fi­ca­tions, in­clud­ing new­ly di­ag­nosed, per­sis­tent and chron­ic, and cor­re­lat­ed with a con­sis­tent re­duc­tion in IgG lev­els.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER